Sophiris Bio Inc. Expected to Post FY2020 Earnings of ($0.24) Per Share (SPHS)
Sophiris Bio Inc. (NASDAQ:SPHS) – Equities researchers at Roth Capital dropped their FY2020 EPS estimates for Sophiris Bio in a note issued to investors on Wednesday. Roth Capital analyst J. Pantginis now expects that the firm will post earnings of ($0.24) per share for the year, down from their prior forecast of ($0.23). Roth Capital has a “Buy” rating and a $8.00 price objective on the stock.
A number of other brokerages have also weighed in on SPHS. Maxim Group boosted their target price on shares of Sophiris Bio from $4.00 to $6.00 and gave the company a “buy” rating in a research note on Wednesday, August 10th. Piper Jaffray Cos. initiated coverage on shares of Sophiris Bio in a research note on Tuesday, August 30th. They set an “overweight” rating and a $7.00 target price for the company.
Shares of Sophiris Bio (NASDAQ:SPHS) traded down 3.9182% during trading on Monday, hitting $2.6999. 597,953 shares of the stock were exchanged. Sophiris Bio has a one year low of $0.80 and a one year high of $8.55. The company’s market cap is $61.07 million. The stock’s 50 day moving average price is $2.87 and its 200-day moving average price is $2.81.
Several large investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in Sophiris Bio by 90.3% in the second quarter. Vanguard Group Inc. now owns 331,000 shares of the biopharmaceutical company’s stock valued at $712,000 after buying an additional 157,100 shares during the period. Airain ltd raised its stake in Sophiris Bio by 99.1% in the third quarter. Airain ltd now owns 63,730 shares of the biopharmaceutical company’s stock valued at $198,000 after buying an additional 31,713 shares during the period. Citadel Advisors LLC raised its stake in Sophiris Bio by 65.2% in the second quarter. Citadel Advisors LLC now owns 49,176 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 19,402 shares during the period. KCG Holdings Inc. raised its stake in Sophiris Bio by 152.3% in the third quarter. KCG Holdings Inc. now owns 42,920 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 25,907 shares during the period. Finally, JPMorgan Chase & Co. bought a new stake in Sophiris Bio during the third quarter valued at approximately $139,000. Hedge funds and other institutional investors own 5.61% of the company’s stock.
About Sophiris Bio
Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).
Receive News & Stock Ratings for Sophiris Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc. and related stocks with our FREE daily email newsletter.